BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

Stock Information for BioVie Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioVie Inc.

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded
BioVie Inc. Announces Closing of Registered Direct Offering
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.